Last reviewed: September 22, 2025 What this article covers: why the psychedelic facilitator–client relationship is often more important than the medicine itself, what training and qualities matter most, how cultural fit shapes outcomes, and how seekers can evaluate...
FDA Publishes MDMA CRL, Exposes Safety and Durability Concerns for Psychedelic Therapies The US Food and Drug Administration announced on September 4, 2025 that it will publish Complete Response Letters promptly after they are issued, and it released a batch of 89...
Single dose of MM120 (LSD) shows lasting reduction in generalized anxiety disorder, JAMA reports Why this matters: A randomized, placebo-controlled Phase 2b trial published in JAMA found that a single oral dose of MM120, an investigational LSD formulation,...
In a quiet lab corner, something unexpected happened. Mice given psilocybin didn’t just survive longer—they seemed to age differently. According to new peer-reviewed research published in npj Aging, female rodents treated with psilocybin over time...
In recent years, ketamine therapy has emerged as one of the most promising tools in the psychedelic-assisted therapy landscape. Originally developed as an anesthetic, ketamine is now showing remarkable potential for conditions like depression, PTSD, and...
It starts innocently enough. You’re prepping for a solo psilocybin experience. You dim the lights, queue your playlist, and open an app that promises structured prompts, real-time check-ins, and therapeutic journaling support. No human needed. It’s like having a guide...
